Vanda Pharmaceuticals Inc. is looking to add imsidolimab to its product portfolio for rare orphan disorders ... as well as its anti-inflammatory portfolio that includes Ponvory® for multiple sclerosis ...

In the assessment of 12-month price targets, analysts unveil insights for Vanda Pharma, presenting an average target of $18.4 ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.

No recommendations, no algorithms, just what Iconfactory calls a “personal, unified timeline” of content you care about. Tapestry has a bunch of clever ways to filter your content, too.

H.C. Wainwright maintained a Buy rating on Vanda Pharmaceuticals (NASDAQ:VNDA) with a price target of $18.00, representing significant upside potential from the current price of $4.31. According to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

WASHINGTON and SAN DIEGO, Feb. 3, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda ... "We are excited to add imsidolimab to Vanda's product portfolio for rare orphan disorders, as well ...

“We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan ... as the anti-inflammatory portfolio that includes Ponvory ® for multiple sclerosis, psoriasis and ulcerative ...

Vanda Pharmaceuticals (VNDA ... “We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan disorders, as well as explore the potential of this IL-36 signal regulator ...

"We are excited to add imsidolimab to Vanda's product portfolio for rare orphan disorders ... in the US and EU as well as the anti-inflammatory portfolio that includes Ponvory ® for multiple sclerosis ...

Vanda Pharmaceuticals Inc. and AnaptysBio Inc. have announced ... “We are excited to add imsidolimab to Vanda’s product portfolio for rare orphan disorders, as well as explore the potential of this IL ...